Medexus Pharmaceuticals Inc. MEDXF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.42% | -2.24% | -8.31% | -9.23% | -0.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.42% | -2.24% | -8.31% | -9.23% | -0.63% |
| Cost of Revenue | -2.34% | -11.56% | -20.86% | -21.00% | -9.06% |
| Gross Profit | 7.03% | 3.97% | 0.55% | -0.66% | 5.52% |
| SG&A Expenses | 1.84% | 3.80% | 6.26% | 14.74% | 14.92% |
| Depreciation & Amortization | 7.33% | 18.64% | 35.61% | 56.91% | 53.77% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.70% | -1.05% | -3.02% | 1.10% | 6.71% |
| Operating Income | 31.56% | -15.90% | -51.05% | -74.14% | -53.26% |
| Income Before Tax | -304.89% | -1,640.65% | -257.92% | -100.78% | -72.99% |
| Income Tax Expenses | 1,328.57% | 96.62% | 114.87% | 166.22% | 103.59% |
| Earnings from Continuing Operations | -424.93% | -393.55% | -206.54% | -107.64% | -83.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -424.93% | -393.55% | -206.54% | -107.64% | -83.40% |
| EBIT | 31.56% | -15.90% | -51.05% | -74.14% | -53.26% |
| EBITDA | 17.06% | 1.03% | -18.72% | -36.22% | -19.81% |
| EPS Basic | -316.86% | -331.75% | -177.59% | -106.88% | -81.62% |
| Normalized Basic EPS | 243.57% | -28.71% | -92.82% | -120.43% | -117.36% |
| EPS Diluted | -319.41% | -333.87% | -177.96% | -107.02% | -81.80% |
| Normalized Diluted EPS | 243.57% | -22.80% | -92.67% | -120.59% | -117.53% |
| Average Basic Shares Outstanding | 7.70% | 15.98% | 25.15% | 28.99% | 21.70% |
| Average Diluted Shares Outstanding | 7.70% | 15.10% | 24.13% | 27.88% | 20.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |